Patents Assigned to CALITHERA BIOSCIENCES INC.
  • Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
    Patent number: 11370754
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 28, 2022
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Michael Van Zandt, Jennifer L. Savoy
  • Solid state forms of fused heteroaromatic pyrrolidinones
    Patent number: 11352355
    Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: June 7, 2022
    Assignee: Calithera Biosciences, Inc.
    Inventors: Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
  • Arginase inhibitor combination therapies
    Patent number: 11291674
    Abstract: The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: April 5, 2022
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Amani Makkouk, Matthew I. Gross, Francesco Parlati
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11208414
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: December 28, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11174261
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: November 16, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210261573
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11078228
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 3, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11034715
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 15, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Compositions and methods for inhibiting arginase activity
    Patent number: 11021495
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • METHOD OF PREPARING (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE
    Publication number: 20210155589
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 27, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Michael VAN ZANDT, Jennifer L. SAVOY
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210077510
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10940148
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210061822
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10905701
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 2, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
    Patent number: 10906872
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 2, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Michael C. Van Zandt, Jennifer L. Savoy
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10851118
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 1, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10844080
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: November 24, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200339607
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 29, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
  • Heterocyclic glutaminase inhibitors
    Patent number: 10793535
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 6, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200223872
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE